Artificial Intelligence to Predict Surgical Outcomes and Assess Pain Neuromodulation in Trigeminal Neuralgia Subjects

Sponsor
IRCCS San Raffaele (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05810428
Collaborator
(none)
50
1
3
36
1.4

Study Details

Study Description

Brief Summary

Trigeminal neuralgia (TN) is the most common cause of facial pain. Medical treatment is the first therapeutic choice whereas surgery, including Gamma Knife radiosurgery (GKRS), is indicated in case of pharmacological therapy failure. However, about 20% of subjects lack adequate pain relief after surgery. Virtual reality (VR) technology has been explored as a novel tool for reducing pain perception and might be the breakthrough in treatment-resistant cases. The investigators will conduct a prospective randomized comparative study to detect the effectiveness of GKRS aided by VR-training vs GKRS alone in TN patients. In addition, using MRI and artificial intelligence (AI), the investigators will identify pre-treatment abnormalities of central nervous system circuits associated with pain to predict response to treatment. The investigators expect that brain-based biomarkers, with clinical features, will provide key information in the personalization of treatment options and bring a huge impact in the management and understanding of pain in TN.

Condition or Disease Intervention/Treatment Phase
  • Procedure: GKRS-VR training
  • Procedure: Control Group
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Single centre, randomized controlled trial, assessor blinded. The investigators plan to enroll 50 TN patients with indications to undergo surgical treatment. Fifty TN participants will be randomly allocated into two groups: individuals in the experimental group (GKRS-VR) will undergo GKRS followed by immersive VR-based sensorimotor neuromodulation training, whilst control group (CT) will undergo only GKRS. A group of 50 age- and sex-matched controls will also be recruited.Single centre, randomized controlled trial, assessor blinded. The investigators plan to enroll 50 TN patients with indications to undergo surgical treatment. Fifty TN participants will be randomly allocated into two groups: individuals in the experimental group (GKRS-VR) will undergo GKRS followed by immersive VR-based sensorimotor neuromodulation training, whilst control group (CT) will undergo only GKRS. A group of 50 age- and sex-matched controls will also be recruited.
Masking:
Single (Outcomes Assessor)
Masking Description:
Physiotherapist, neurologists, neuropsychologists, radiologist and biomedical engineering assessing the patients are blinded to group allocation.
Primary Purpose:
Treatment
Official Title:
Artificial Intelligence to Predict Surgical Outcomes and Assess Pain Neuromodulation in Trigeminal Neuralgia Subjects
Anticipated Study Start Date :
Apr 30, 2023
Anticipated Primary Completion Date :
Nov 30, 2025
Anticipated Study Completion Date :
Apr 30, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: GKRS-VR training

GKRS-VR group will undergo GKRS and neuromodulation based on Virtual Reality sensorimotor rehabilitation using an immersive system

Procedure: GKRS-VR training
One month after radiosurgery, GKRS-VR subjects will receive neuromodulation treatment twice a week (30' per time), for 8 consecutive weeks followed by 9 months of remote rehabilitation. GKRS-VR group will perform neuromodulation based on VR sensorimotor rehabilitation using an immersive system developed ad-hoc. Treatments will include voluntary mimic movements reinforced by VR augmented feedback, consisting in the reflection of a real-time avatar animation, multiplied when needed, associated with different targets to reach based on specific facial gestures. The execution of motion multiplier on avatar will be allowed in order to personalize treatments, emphasizing a graded exposure to pain perception. In addition, the investigators will develop a dedicated mobile-application for remote rehabilitation with the aim of prescribing VR augmented feedback home exercises and immersive VR pain neuromodulation.

Active Comparator: Control Group

Control group (CT) will undergo only GKRS

Procedure: Control Group
Control Group will undergo only radiosurgery with no rehabilitation and they will perform only clinical evaluation at study entry, after three months and one year.

No Intervention: Healthy subjects

Age- and sex-matched healthy subjects recruited to compare neuropsychological,clinical and structural/functional magnetic resonance imaging characteristics at baseline.

Outcome Measures

Primary Outcome Measures

  1. Numeric Rating Scale for pain (NRS) changes [Baseline, month 3 and month 12]

    Changes in time in the Numeric rating scale (NRS): a pain screening tool, commonly used to assess pain severity at that moment in time using a 0-10 scale, with zero meaning "no pain" and 10 meaning "the worst pain imaginable"

  2. Barrow Neurological Institute (BNI) pain score changes [Baseline, month 3 and month 12]

    Changes in time in the Barrow Neurological Institute (BNI) pain intensity scale to assess the level of pain in patients with trigeminal neuralgia. BNI values I-III were considered to indicate good outcomes whereas BNI values IV and V indicate poor response to treatment.

Secondary Outcome Measures

  1. McGill Pain Questionnaire (MPQ) changes [Baseline, month 3 and month 12]

    The McGill Pain Questionnaire (MPQ) can be used to evaluate a person experiencing significant pain. It can be used to monitor the pain over time and to determine the effectiveness of any intervention. The users are presented with a list of 78 words in 20 sections that are related to pain.The users mark the words that best describe their pain (multiple markings are allowed). Among the words, sections of these words signify different components of pain, namely, Sensory (sections 1-10), Affective (sections 11-15), Evaluative (section 16), and Miscellaneous (sections 17-20).

  2. Pain Catastrophizing Scale (PCS) [Baseline, month 3 and month 12]

    The Pain Catastrophizing Scale (PCS) assesses the extent of catastrophic thinking. It is a 13-item scale, with a total range of 0 to 52. Higher scores are associated with higher amounts of pain catastrophizing.

  3. Central Sensitization Inventory (CSI) changes [Baseline, month 3 and month 12]

    The Central Sensitisation Inventory (CSI) is a self-report outcome measure designed to identify patients who have symptoms that may be related to central sensitisation.The CSI consists of two parts: Part A includes 25 questions related to common central sensitivity syndromes symptoms.Part B determines if the patient has been diagnosed with certain central sensitivity syndromes disorders or related disorders, such as anxiety and depression.

  4. Tampa Scale of Kinesiophobia (TSK) changes [Baseline, month 3 and month 12]

    The Tampa Scale for Kinesiophobia (TSK) is a 17-item questionnaire that quantifies fear of movement. Individual item scores range from 1-4, with the negatively worded items (4,8,12,16) having a reverse scoring (4-1). The 17 item TSK total scores range from 17 to 68 where the lowest 17 means no or negligible kinesiophobia, and the higher scores indicate an increasing degree of kinesiophobia.

  5. Craniofacial Pain and Disability Inventory (CFPDI) changes [Baseline, month 3 and month 12]

    Craniofacial Pain and Disability Inventory (CF-PDI) can be used in research and clinical practice for the assessment of patients with craniofacial pain. It is a 21-item measure and patients give their answers using a 4-point Likert scale scoring from 1 (no problem) to 4 (maximum problem). The scale presents two factors, named Pain and disability (14 items) and Jaw functional status (7 items). The scores of the responses are added with higher scores indicating greater problems

  6. Penn Facial Pain Scale (PFPS) changes [Baseline, month 3 and month 12]

    The Penn Facial Pain Scale (Penn-FPS) was originally developed in order to fully assess the impact of trigeminal neuralgia pain on patients' health-related quality of life. It is a 7-item scale, with a total range of 0 to 10.

  7. Percentage of displacement of virtual face landmarks [Baseline, month 3 and month 12]

    Percentage of displacement of virtual face landmarks

  8. 12-item Allodynia Symptom Checklist (ASC-12) scale changes [Baseline, month 3 and month 12]

    presence of allodynia and hypoesthesia; It is a 12-item scale, with a total range of 0 to 12.

  9. Trigeminal reflexes testing [Baseline, month 3 and month 12]

    A series of reflex responses after electrical stimulation of the ophthalmic division (R1 and R2) and maxillary/mandibular division (SP1 and SP2) of the trigeminal nerve

  10. Longitudinal changes of brain gray matter volumes [Baseline, month 3 and month 12]

    3D T1-weighted sequence wil be used to evaluate cortical thickness and subcortical volume changes

  11. Longitudinal changes of white matter microstructural abnormalities [Baseline, month 3 and month 12]

    White matter damage will be evaluated on diffusion-tensor MRI sequence

  12. Resting-State Functional Connectivity MRI changes [Baseline, month 3 and month 12]

    Longitudinal changes will be evaluated on functional MRI sequences

  13. Functional MRI changes [Baseline, month 3 and month 12]

    Functional MRI will be acquired on a 3T scanner during the performance of a task, in which participants will be asked to observe facial gestures during activities of daily living or specific movements different for each subject depending on which action triggers the facial pain.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • diagnosis of TN according to the International Classification of Headache Disorders, third edition (ICHD-3) criteria;

  • age >18 years;

  • indication to undergo radiosurgical treatment;

  • willingness and ability to comply with scheduled visits and other trial procedures.

Exclusion Criteria:
  • Any person unable to lie still within the environment of the MRI scanner for the required period to perform the study and those where MRI scanning is contraindicated;

  • metal implants, pacemaker, etc.;

  • Pregnancy or breastfeeding;

  • Any significant psychiatric disease;

  • Use of illicit drugs;

  • Brain pathology shown by brain MRI and/or neurophysiological examination;

  • Any person unable to understand and follow the instructions of the investigators;

  • Any other condition according to the Investigator would make the subject unsuitable for the study.

Contacts and Locations

Locations

Site City State Country Postal Code
1 IRCCS San Raffaele Milan Italy 20132

Sponsors and Collaborators

  • IRCCS San Raffaele

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Prof. Massimo Filippi, Prof., IRCCS San Raffaele
ClinicalTrials.gov Identifier:
NCT05810428
Other Study ID Numbers:
  • GR-2021-12374601
First Posted:
Apr 12, 2023
Last Update Posted:
Apr 12, 2023
Last Verified:
Apr 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 12, 2023